Pancreatic Cancer Research

ResearcherUniversità Campus Bio-MedicoActive in the last 2 years

Roberto Coppola

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5798-0714; OpenAlex author ID A5060064110. Sources: OpenAlex.

Their work

Papers
29 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
48
Papers, trials and grants by year

2014: 3 papers · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 4 papers · 2022: 2 papers · 2023: 5 papers · 2024: 2 papers · 2025: 3 papers · 2026: 3 papers

Papers 29

  1. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18479-z↗
  2. Plasma Protein Corona Fingerprinting Across Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma: A Comparative Proof-of-Concept Study. Co-author DOI 10.3390/cancers18203275↗
  3. Pancreatic Steatosis as a Risk Phenotype for Pancreatic Ductal Adenocarcinoma: A Narrative Review. Co-author DOI 10.3390/medicina62040729↗
  4. Nanoparticle-protein corona enhances accuracy of Ca-19.9-based pancreatic cancer classification. Co-author DOI 10.1039/d4nr02435d↗
  5. Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18212-w↗
  6. Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma: Aligning Guideline Recommendations with Real-World Evidence. Co-author DOI 10.3390/cancers17183085↗
  7. The impact of intensified staging and combined therapies in locally advanced pancreatic cancer: a secondary analysis of prospective studies. Co-author DOI 10.1097/js9.0000000000000755↗
  8. Updates on pancreatic cancer treatment - invited special issue. First author DOI 10.1097/js9.0000000000002086↗
  9. Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review. Co-author DOI 10.21037/jgo-22-1034↗
  10. Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15072013↗
  11. Stratifying Risk for Pancreatic Cancer by Multiplexed Blood Test. Co-author DOI 10.3390/cancers15112983↗
  12. Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going. Co-author DOI 10.3390/jcm12113677↗
  13. Role of preoperative sarcopenia in predicting postoperative complications and survival after pancreatoduodenectomy for pancreatic cancer. Co-author PMID 36810297↗
  14. Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives. Co-author DOI 10.3390/biomedicines10092091↗
  15. Multiplexed Detection of Pancreatic Cancer by Combining a Nanoparticle-Enabled Blood Test and Plasma Levels of Acute-Phase Proteins. Co-author DOI 10.3390/cancers14194658↗
  16. Efficient pancreatic cancer detection through personalized protein corona of gold nanoparticles. Co-author DOI 10.1116/6.0000540↗
  17. CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. Co-author DOI 10.3389/fonc.2021.690580↗
  18. Detection of Pancreatic Ductal Adenocarcinoma by Ex Vivo Magnetic Levitation of Plasma Protein-Coated Nanoparticles. Co-author DOI 10.3390/cancers13205155↗
  19. Nanotechnology and pancreatic cancer management: State of the art and further perspectives. Co-author DOI 10.4251/wjgo.v13.i4.231↗
  20. Personalized Graphene Oxide-Protein Corona in the Human Plasma of Pancreatic Cancer Patients. Co-author DOI 10.3389/fbioe.2020.00491↗
  21. A Bio-Imaging Signature as a Predictor of Clinical Outcomes in Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers12082016↗
  22. Synergistic Analysis of Protein Corona and Haemoglobin Levels Detects Pancreatic Cancer. Co-author DOI 10.3390/cancers13010093↗
  23. Protein Corona Fingerprints of Liposomes: New Opportunities for Targeted Drug Delivery and Early Detection in Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics11010031↗
  24. Improving the accuracy of pancreatic cancer clinical staging by exploitation of nanoparticle-blood interactions: A pilot study. Last author DOI 10.1016/j.pan.2018.06.002↗
  25. Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic canc… Last author DOI 10.1038/srep45845↗
  26. hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2015.28↗
  27. Size and charge of nanoparticles following incubation with human plasma of healthy and pancreatic cancer patients. Last author DOI 10.1016/j.colsurfb.2014.10.008↗
  28. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature. Last author DOI 10.1016/j.pan.2014.07.002↗
  29. Reply to 'Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma' (Am Surg 2012;78:225-9). Last author DOI 10.1177/000313481408000130↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Damiano D. Caputo · 22 shared papers, 2014–2026 · strength 3.61
  2. Vincenzo La Vaccara · 11 shared papers, 2021–2026 · strength 2.32
  3. Roberto Cammarata · 8 shared papers, 2022–2026 · strength 1.86
  4. Alessandro Coppola · 10 shared papers, 2020–2024 · strength 1.54
  5. Giulio Caracciolo · 11 shared papers, 2014–2025 · strength 1.48
  6. Daniela Pozzi · 11 shared papers, 2014–2025 · strength 1.48
  7. Luca Digiacomo · 9 shared papers, 2018–2025 · strength 1.26
  8. Erica Quagliarini · 6 shared papers, 2020–2025 · strength 0.93
  9. Sara Ramella · 6 shared papers, 2017–2024 · strength 0.81
  10. Michele Fiore · 6 shared papers, 2017–2024 · strength 0.81
  11. Sara Elsa Aita · 2 shared papers, 2026 · strength 0.62
  12. Kevin C. Conlon · 1 shared paper, 2024 · strength 0.46
  13. Sara Palchetti · 4 shared papers, 2018–2021 · strength 0.44
  14. Allegra Ripolli · 2 shared papers, 2025–2026 · strength 0.41
  15. Kongyuan Wei · 2 shared papers, 2025–2026 · strength 0.41
  16. Emanuele F. Kauffmann · 2 shared papers, 2025–2026 · strength 0.41
  17. Riccardo Casadei · 2 shared papers, 2025–2026 · strength 0.41
  18. Sergio Alfieri · 2 shared papers, 2025–2026 · strength 0.41
  19. V. Egorov · 2 shared papers, 2025–2026 · strength 0.41
  20. Gregory G. Tsiotos · 2 shared papers, 2025–2026 · strength 0.41
  21. Alessandro Zerbi · 2 shared papers, 2025–2026 · strength 0.41
  22. Yuichi Nagakawa · 2 shared papers, 2025–2026 · strength 0.41
  23. Niccolò Napoli · 2 shared papers, 2025–2026 · strength 0.41
  24. Benedetto Ielpo · 2 shared papers, 2025–2026 · strength 0.41
  25. Elena B. Rangelova · 2 shared papers, 2025–2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.